Table 2 Immune checkpoint inhibitor agent administered by malignancy type
| Â | No. (%) | |||
|---|---|---|---|---|
Checkpoint inhibitor | Melanoma n = 120 | Solid tumor n = 148 | Hematologic cancer n = 59 | P |
Ipilimumab | 81 (68) | 44 (30) | 13 (22) | < 0.001 |
Nivolumab | 7 (6) | 62 (42) | 31 (53) | Â |
Pembrolizumab | 23 (19) | 31 (21) | 15 (25) | Â |
Combinationa | 9 (8) | 10 (7) | 0 (0) | Â |
Atezolizumab | 0 (0) | 1 (1) | 0 (0) | Â |